GERN
NASDAQ
$1.44
Geron Corp (GERN)
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The company is headquartered in Foster City, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $3.40 (+136.11%)
Market Cap
$951M
Revenue 5Y CAGR
+257.04%
Free Cash Flow Yield
-13.31%
Beta (5Y)
1.16
Price Chart
Valuation
Market Cap$951M
P/S4.51
P/B3.98
Profitability
Total Revenue (TTM)$196M
Gross Profit (TTM)$120M
EBITDA-$37M
Profit Margin-7%
Operating Margin-0.5%
EPS-$0.10
Financial Health
Debt-to-Equity109.9%
Free Cash Flow Yield-13.31%
Growth & Risk
EPS 5Y CAGR-18.28%
Revenue 5Y CAGR+257.04%
FCF 5Y CAGR+11.49%
Beta (5Y)1.16
Sharpe Ratio0.42